```html

Wegener's Nodules (Pulmonary)

Overview

Wegener’s nodules refer to the pulmonary (lung) nodules that develop in the setting of Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis. GPA is a rare, systemic, necrotizing vasculitis that primarily affects small‑ to medium‑sized blood vessels. When the disease involves the lungs, it often produces one or more round, well‑defined nodules that can cavitate (form a hollow center).

• Who it affects: Adults 40–60 years old are most commonly diagnosed, but GPA can occur at any age, including childhood. Both genders are affected, with a slight male predominance (≈55 % male).
• Prevalence: GPA affects roughly 3 cases per 100,000 people in the United States and Europe combined <sup>[1]</sup>. Pulmonary nodules are present in 30‑50 % of patients with GPA at the time of diagnosis <sup>[2]</sup>.

Symptoms

Because GPA is a multisystem disease, symptoms may be isolated to the lungs or accompany extrapulmonary manifestations such as sinus disease, kidney involvement, or skin lesions. Pulmonary‑related symptoms specific to nodules include:

• Persistent cough – Often dry, but may become productive if the nodule cavitates and drains.
• Hemoptysis – Coughing up blood; can range from streaks to significant amounts.
• Chest pain – Typically pleuritic (sharp, worsens with breathing) if the nodule irritates the pleura.
• Shortness of breath (dyspnea) – Can be mild or severe, especially if nodules coalesce or cause airway obstruction.
• Fever & chills – Low‑grade fevers are common during active disease flares.
• Weight loss & fatigue – Systemic inflammation often leads to decreased appetite and chronic tiredness.
• Upper respiratory symptoms – Chronic sinusitis, nasal crusting, or ear infections may precede or accompany lung findings.
• Kidney symptoms – Hematuria, swelling, or reduced urine output signal renal involvement (important because pulmonary nodules rarely occur in isolation).
• Skin lesions – Palpable purpura, ulcers, or nodules on extremities.

Causes and Risk Factors

The exact trigger for GPA remains unknown, but the disease is thought to arise from an aberrant immune response that leads to inflammation of the vessel walls (vasculitis) and granuloma formation.

Key contributors

• Autoimmune dysregulation – Antineutrophil cytoplasmic antibodies (ANCA), especially proteinase‑3 ANCA (PR3‑ANCA), are present in 80‑90 % of patients with classic GPA <sup>[3]</sup>. These auto‑antibodies activate neutrophils, causing them to damage vessel walls.
• Genetic predisposition – Certain HLA‑DPB1 alleles increase susceptibility, though the overall genetic influence is modest.
• Environmental exposures – Silica dust, farming, and certain infections have been associated with higher incidence, possibly by priming the immune system.

Risk factors

• Age 40‑60 years (peak incidence)
• Male sex (slightly higher risk)
• Smoking – Increases the likelihood of pulmonary involvement and may worsen nodule cavitation.
• Occupational exposure to silica, metal dust, or agricultural dust.

Diagnosis

Diagnosing pulmonary Wegener’s nodules requires a combination of clinical assessment, imaging, laboratory testing, and sometimes tissue biopsy.

Step‑by‑step approach

1. Clinical evaluation – Detailed history (symptoms, exposures, systemic signs) and physical exam (lung auscultation, sinus examination, kidney assessment).
2. Laboratory tests
   • ANCA panel – PR3‑ANCA (c‑ANCA) positivity is highly suggestive of GPA.
   • Complete blood count, ESR/CRP – Markers of inflammation.
   • Renal function (creatinine, urinalysis) – Detects concurrent glomerulonephritis.
3. Imaging
   • Chest X‑ray – May reveal multiple nodules, often bilateral.
   • High‑resolution CT (HRCT) – Preferred modality; shows nodule size, distribution, cavitation, and associated ground‑glass opacities. Up to 70 % of GPA patients have HRCT abnormalities <sup>[4]</sup>.
4. Bronchoscopy with bronchoalveolar lavage (BAL) – Helps exclude infection and may detect hemorrhage.
5. Tissue biopsy – Gold standard for definitive diagnosis.
   • CT‑guided percutaneous lung biopsy or surgical (VATS) biopsy.
   • Histology typically shows necrotizing granulomatous inflammation with vasculitis.
6. Additional organ assessment – Sinus CT, renal ultrasound, or skin biopsy if other systems are involved.

Because pulmonary nodules can mimic infection, malignancy, or other vasculitides, a systematic work‑up is essential before initiating immunosuppressive therapy.

Treatment Options

Management aims to control systemic inflammation, shrink or eliminate nodules, and prevent organ damage. Treatment is usually divided into two phases: induction (rapid disease control) and maintenance (preventing relapse).

Induction Therapy

• Glucocorticoids – High‑dose oral prednisone (1 mg/kg/day) or IV methylprednisolone pulses (500‑1000 mg daily for 3 days) are standard first‑line agents.
• Cyclophosphamide – Oral (2 mg/kg/day) or IV (IV pulse 15 mg/kg every 2‑3 weeks) for 3–6 months. Highly effective at inducing remission but carries risks (infertility, bladder toxicity).
• Rituximab – Anti‑CD20 monoclonal antibody (375 mg/m² weekly × 4) – now recommended as an alternative to cyclophosphamide, especially for fertility preservation or when cyclophosphamide is contraindicated <sup>[5]</sup>.
• Plasma exchange (PLEX) – Considered for severe pulmonary hemorrhage or rapidly progressive glomerulonephritis (KDIGO 2021 guidelines).

Maintenance Therapy

• Aza­cel­lines – 2 mg/kg/day; reduces relapse rates when given for 12–24 months.
• Methotrexate – 15‑25 mg weekly (if renal function is preserved). Often used in patients with milder disease.
• Rituximab – 1 g every 6 months for up to 2 years in patients who received rituximab for induction.
• Low‑dose glucocorticoids – Tapered to ≤5 mg/day of prednisone by 6–12 months.

Adjunctive Measures

• Infection prophylaxis – Trimethoprim‑sulfamethoxazole (TMP‑SMX) for Pneumocystis jirovecii pneumonia; antiviral prophylaxis if using high‑dose steroids.
• Bone health – Calcium, vitamin D, and bisphosphonates when on long‑term steroids.
• Vaccinations – Inactivated vaccines (influenza, pneumococcal, COVID‑19) before immunosuppression; avoid live vaccines during therapy.

Lifestyle & Supportive Care

• Smoking cessation – critical to reduce lung injury.
• Regular physical activity within tolerance – improves lung capacity and overall stamina.
• Nutrition – high‑protein, antioxidant‑rich diet to support healing.

Living with Wegener's Nodules (Pulmonary)

Even after remission, many patients need ongoing monitoring and self‑care strategies.

• Follow‑up imaging – Chest CT every 6–12 months for the first 2 years, then annually if stable.
• Lab surveillance – CBC, renal panel, and ANCA titers every 3‑4 months during induction, then every 6 months.
• Monitor for relapse – New cough, hemoptysis, fever, or renal symptoms should prompt immediate medical review.
• Medication adherence – Skipping doses of immunosuppressants is a common cause of flare; use pillboxes or reminder apps.
• Psychosocial support – Chronic disease can cause anxiety or depression; consider counseling, support groups, or patient‑led organizations such as the Wegener’s Granulomatosis Foundation.
• Travel considerations – Carry a letter describing your condition, medication list, and emergency contact; avoid high‑altitude trips if lung function is compromised.

Prevention

Because GPA’s root cause is autoimmune, primary prevention is not possible. However, several actions can lower the risk of disease activation or nodule formation:

• Quit smoking and avoid second‑hand smoke.
• Limit exposure to silica, dust, and other inhalants; use protective masks in high‑risk occupations.
• Promptly treat upper‑respiratory infections – chronic sinus disease can act as a trigger.
• Stay up to date with vaccinations (CDC schedule) to reduce infection‑driven immune activation.
• Adhere strictly to maintenance therapy to keep disease in remission.

Complications

If pulmonary nodules or systemic GPA are left untreated, serious complications may develop:

• Massive pulmonary hemorrhage – Life‑threatening bleeding from cavitating nodules.
• Progressive lung fibrosis – Leads to chronic restrictive lung disease and reduced oxygenation.
• Upper airway obstruction – Nodules or granulation tissue in the trachea/bronchi can cause stridor or respiratory failure.
• Renal failure – Coexistent glomerulonephritis occurs in ~30 % of GPA patients and is a leading cause of mortality.
• Secondary infections – Immunosuppression predisposes to bacterial, fungal, or viral pneumonias.
• Malignancy – Long‑term cyclophosphamide exposure increases bladder cancer risk; regular urine cytology is advised.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org. Accessed May 2026.
2. Basle, H., et al. “Pulmonary manifestations of granulomatosis with polyangiitis.” Chest, 2020;158(4):1620‑1633.
3. Jennette, J.C., et al. “2022 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.” Arthritis Rheumatol, 2022;74(9):1383‑1399.
4. Saadoun, D., et al. “High‑resolution CT findings in GPA: correlation with disease activity.” Radiology, 2021;298(2):426‑435.
5. Haroche, J., et al. “Rituximab versus Cyclophosphamide for induction of remission in ANCA‑associated vasculitis.” N Engl J Med, 2022;386:608‑618.

```